PHILADELPHIA, July 25, 2025 /PRNewswire/ -- Berger Montague PC, a national securities litigation law firm announces it is investigating potential securities fraud claims involving RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST), following the recent filing of a federal securities class action lawsuit.

The lawsuit alleges that Defendants failed to disclose to investors that: (1) RxSight was experiencing "adoption challenges" and/or structural issues resulting in declines in sales and utilization; (2) Defendants had overstated the demand for RxSight's products; and (3) as a result, RxSight was unlikely to meet its own previously issued financial guidance for fiscal year 2025.

LOS ANGELES, July 25, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of RxSight, Inc. ("RxSight" or "the Company") (NASDAQ: RXST) for violations of the securities laws.

INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. RxSight reported its financial results for the second quarter of 2025 on July 9, 2025. The Company reported declines in key metrics including sales of Light Delivery Devices ("LDD") along with a decline in total revenue across the organization. The Company also lowered its guidance for its full year financial performance, blaming the change in part on "adoption challenges" that have caused an "LDD stall." Based on its financial performance, shares of RxSight fell by just under 38% on the same day.

LOS ANGELES, July 25, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against RxSight, Inc. ("RxSight" or "the Company") (NASDAQ: RXST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between November 7, 2024 and July 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before September 22, 2025.

SAN DIEGO, July 23, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the RxSight class action lawsuit – captioned Makaveev v. RxSight, Inc., No. 25-cv-01596 (C.D. Cal.) – seeks to represent purchasers or acquirers of RxSight, Inc. (NASDAQ: RXST) securities and charges certain of RxSight's top executives with violations of the Securities Exchange Act of 1934.

NEW YORK, July 23, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of RxSight, Inc. (NASDAQ: RXST) between November 7, 2024 and July 8, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 22, 2025.

NEW YORK, July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ("RxSight" or the "Company") (NASDAQ: RXST).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  

The investigation concerns whether RxSight and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

LOS ANGELES, July 21, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of RxSight, Inc. ("RxSight" or "the Company") (NASDAQ: RXST) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. RxSight reported its Q2 2025 financial results on July 9, 2025. The Company revealed declines in Light Delivery Devices ("LDD") sales and light adjustable intraocular lenses ("LAL") utilization, along with an overall revenue decline. The Company lowered its guidance for full year 2025, claiming that "Adoption challenges over the last few quarters have been a primary reason for the LDD stall." Based on this news, shares of RxSight fell by 37.8% on July 9, 2025.

NEW YORK, July 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ("RxSight" or the "Company") (NASDAQ: RXST).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  

The investigation concerns whether RxSight and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.